title: Phase II trial of carboplatin in combination with etoposide in locally advanced large cell carcinoma and adenocarcinoma of the lung.
abstract: A total of 18 patients with locally advanced (Stage III) adenocarcinoma and large cell undifferentiated carcinoma of the lung, previously untreated, were enrolled in a Phase II trial. Treatment consisted of carboplatin 325 mg/m2, day 1 and etoposide 100 mg/m2 on days 2 and 3. All patients were evaluable for response. Of these, one patient had a partial response (5.5%; confidence interval 0-24%). Toxicity comprised mainly leukopenia and anaemia. Other toxicities were mild. This Phase II study evidenced a poor response rate for these regimes on adenocarcinoma and large cell undifferentiated carcinoma of the lung.
authors.affiliation: Service of Oncology, Hospital de Santa Caterina, Girona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Fuentes
authors.forename: J
authors.initials: J
authors.lastname: Dorca
authors.forename: E
authors.initials: E
authors.lastname: Canals
authors.forename: A
authors.initials: A
authors.lastname: Izquierdo
authors.forename: M
authors.initials: M
authors.lastname: Beltrán
authors.forename: P
authors.initials: P
authors.lastname: Viladiu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018287:Carcinoma, Large Cell / Q000188:drug therapy*; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D005047:Etoposide; D016190:Carboplatin